|Bristol Myers Squibb Co., of New York||Inrebic (fedratinib)||Wild-type and mutationally activated JAK2 and FMS-like tyrosine kinase 3 inhibitor||Newly diagnosed and previously treated myelofibrosis||The European Commission granted full marketing authorization in all EU member states as well as Norway, Iceland and Liechtenstein|
|China Oncology Focus Ltd., of Hong Kong, an affiliate of Lee's Pharmaceutical Holdings Ltd., and Sorrento Therapeutics Inc., of San Diego||Socazolimab||Anti-PD-L1 antibody||Recurrent or metastatic cervical cancer||Received breakthrough therapy designation in China|
|Immunomet Therapeutics Inc., of Houston||IM-156||Protein complex 1 inhibitor||Idiopathic pulmonary fibrosis||FDA cleared the IND application and granted orphan drug designation|
|Navidea Biopharmaceuticals Inc., of Dublin, Ohio||Tc99m tilmanocept||Imaging agent||Rheumatoid arthritis||Submitted its formal type B meeting request to the FDA; the agency will now review the briefing documents containing results from the NAV3-31 phase IIb study and the proposed phase III design and protocol|
|Russian Direct Investment Fund, of Moscow, Astrazeneca plc, of Cambridge, U.K., and University of Oxford||Sputnik V and COVID-19 Vaccine Astrazeneca||Vaccines||COVID-19 prophylaxis||The Ministry of Health of Azerbaijan issued a permit to conduct clinical trials of a combined use of the 2 vaccines; trials will begin at the end of February|
|Russian Direct Investment Fund, of Moscow||Sputnik V||COVID-19 spike glycoprotein modulator||COVID-19 prophylaxis||Mongolia granted emergency use authorization; approved under the emergency use authorization procedure in Pakistan|
|Triastek Inc., of Nanjing, China||T-19||3D-printed drug product that functions as a chronotherapeutic drug delivery system||Rheumatoid arthritis||FDA approved the IND 505(b)(2) application|
For more information about individual companies and/or products, see Cortellis.